期刊文献+

微小RNA-221通过靶基因细胞因子信号抑制因子1表达水平调控前列腺癌细胞的侵袭力 被引量:3

Regulation of prostate cancer cells invasiveness via microRNA -221 by the expression level of target gene suppressor of cytokine signaling 1
原文传递
导出
摘要 目的观察前列腺癌细胞中微小RNA(miRNA,miR)-221的表达及其对前列腺癌细胞侵袭力的影响。方法应用实时定量反转录聚合酶链反应(RT-qPCR)检测miR-221在前列腺正常细胞株与前列腺癌细胞株中表达的差异,利用细胞转染构建miR-221过表达和抑制细胞株,再通过细胞迁移实验检测细胞侵袭力的变化;使用荧光素酶报告实验验证miR-221与细胞因子信号抑制因子1(SOCS1)基因的直接调控关系,再采用Western blot检测细胞中SOCS1基因表达水平的变化。结果RT-qPCR检测细胞株可见miR-221在PC3、LNCaP和DU145 3种前列腺癌细胞株中表达量(6.51、7.52和8.03)均比前列腺正常细胞株表达量(12.12)低(F=235.852,P=0.000),其中两两比较差异也有统计学意义。细胞迁移实验结果显示,过表达miR-221的前列腺肿瘤细胞迁移速度显著慢于对照组(25.3 h比17.8 h)。荧光素酶报告实验显示,miR-221能明显抑制SOCS1-3’UTR的荧光素酶活性(P=0.006)。过表达miR-221后,PC3细胞中SOCS1的蛋白表达下调(P=0.035)。结论miR-221负调控SOCS1能抑制前列腺癌细胞的迁移。 ObjectiveTo investigate microRNA (miRNA, miR)-221 expression in prostate cancer cells and its influence on prostate cancer cell invasiveness.MethodsmiR-221 expression levels in prostate cancer cell lines were measured by real-time quantitative reverse transcriptase-polymerase chain reaction (RT-qPCR). The miR-221 overexpression and silencing cell lines were constructed by cell transfection. Effects of the depletion on cell invasiveness were assessed in vitro with Transwell. ResultsRT-qPCR showed miR-221 was down-regulated in PC3, LNCaP and DU145 cells than in PrEC (F=235.852, P=0.000), in which pairwise comparison also had significant differences. Cell invasiveness assay showed that migration of LNCaP (P=0.000) and DU145 (P=0.000) cells overexpressing miR-221 was significantly slower than in the control group. ConclusionThe negative regulation of suppressor of cytokine signaling 1 (SOCS1) by miR-221 can inhibit the invasiveness of prostate cancer cells.
出处 《中华实验外科杂志》 CSCD 北大核心 2017年第10期1664-1666,共3页 Chinese Journal of Experimental Surgery
关键词 前列腺癌 微小RNA-221 侵袭力 细胞因子信号抑制因子1 Prostate cancer MicroRNA - 221 Invasiveness Suppressor of cytokine signa ling 1
  • 相关文献

参考文献3

二级参考文献33

  • 1Zerbe LK, Pino I, Pio R, et al. Relative amounts of antagonistic spli- cing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth:implications for pre-mRNA processing [ J]. Mol Careinog, 2004,41 (4) :187-196.
  • 2Moore M J, Wang Q, Kennedy C J, et al. An alternative splicing network links cell-cycle control to apoptosis [ J ]. Cell, 2010, 142 ( 4 ) : 625- 636.
  • 3Gonalves V, Theisen P, Antunes O, et al. A missense mutation in the APC tumor suppressor gene disrupts an ASF/SF2 splicing enhancer motif and causes pathogenic skipping of exon 14 [J]. Mutat Res, 2009,662(1-2) :33-36.
  • 4Olshavsky NA, Comstock CE, Schiewer M J, et al. Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1 b onco- gene [ J ]. Cancer Res ,2010,70 ( 10 ) :3975-3984.
  • 5Iborra S, Hirschfeld M, Jaeger M, et al. Alterations in expression pat- tern of splicing factors in epithelial ovarian cancer and its clinical im- pact [ J]. Int J Gynecol Cancer,2013,23 (6) :990-996.
  • 6Ezponda T, Pajares M J, Agorreta J, et al. The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression[ J ]. Clin Cancer Res,2010,16(16) :4113-4125.
  • 7Anczuk6w O, Rosenberg AZ, Akerman M, et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epi- thelia/ cell transformation [ J ]. Nat Struct Mol Biol,2012,19 (2) :220- 228.
  • 8Michlewski G, Sanford JR, Cdceres JF. The splicing factor SF2/ASF regulates translation initiation by enhancing phosphorylation of 4E- BP1 [ J]. Mol Cell ,2008,30(2 ) : 179-189.
  • 9Karni R, Hippo Y, Lowe SW, et al. The splicing-factor oncoprotein SF2/ASF activates mTORC1 [J]. Proc Natl Acad Sci U S A,2008, 105(40) :15323-15327.
  • 10Liu LL, Xie N, Sun S, et al. Mechanisms of the androgen receptor spli- cing in prostate cancer cells [ J ]. Oncogene, 2014,33 ( 24 ) : 3140- 3150.

共引文献4

同被引文献27

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部